Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis

The Lancet Infectious Diseases

Volumn 16, Issue 7, 2016, Pages 828-837

  Marty, Francisco M ^a   Ostrosky Zeichner, Luis ^b   Cornely, Oliver A ^c   Mullane, Kathleen M ^d   Perfect, John R ^e,f   Thompson, George R ^g   Alangaden, George J ^h   Brown, Janice M ⁱ   Fredricks, David N ^j   Heinz, Werner J ^k   Herbrecht, Raoul ^l   Klimko, Nikolai ^m   Klyasova, Galina ⁿ   Maertens, Johan A ^o   Melinkeri, Sameer R ^p   Oren, Ilana ^q   Pappas, Peter G ^r   Ráčil, Zdeněk ^s   Rahav, Galia ^t   Santos, Rodrigo ^u   Schwartz, Stefan ^v   Vehreschild, J Janne ^w   Young, Jo Anne H ^x,y   Chetchotisakd, Ploenchan ^z   Jaruratanasirikul, Sutep ^aa   Kanj, Souha S ^ab   Engelhardt, Marc ^ac   Kaufhold, Achim ^ac   Ito, Masanori ^ad   Lee, Misun ^ad   Sasse, Carolyn ^ad   Maher, Rochelle M ^ad   Zeiher, Bernhardt ^ad   Vehreschild, Maria J G T ^m   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF CHICAGO   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DUKE UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Henry Ford Health System Division of Infectious Diseases   (United States)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j USA   (United States)

^k UNIVERSITY OF WÜRZBURG   (Germany)

^l UNIVERSITÉ DE STRASBOURG   (France)

^m NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

ⁿ NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^o UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^p DEENANATH MANGESHKAR HOSPITAL   (India)

^q Unit of Infectious Diseases   (Israel)

^r University of Alabama at Birmingham   (United States)

^s UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^t SHEBA MEDICAL CENTER   (Israel)

^u FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^v CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^w UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^x UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^y UNIVERSITY OF MINNESOTA   (United States)

^z KHON KAEN UNIVERSITY   (Thailand)

^aa PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^ab AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^ac BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

^ad ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ASPARTATE AMINOTRANSFERASE; ISAVUCONAZOLE; ISAVUCONAZONIUM; LIVER ENZYME; POSACONAZOLE; ANTIFUNGAL AGENT; NITRILE; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ANTIFUNGAL ACTIVITY; ARTICLE; BACKACHE; BACTEREMIA; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; ESCHERICHIA COLI INFECTION; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; INSOMNIA; LIVER INJURY; MALE; MIDDLE AGED; MORTALITY; MUCORMYCOSIS; MULTICENTER STUDY; NAUSEA; NONHUMAN; OPEN STUDY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ANIMAL; ASPERGILLOSIS; CLINICAL TRIAL; FUNGUS; INTRAVENOUS DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ADULT; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; FEMALE; FUNGI; HUMANS; MALE; MIDDLE AGED; MUCORMYCOSIS; NITRILES; PYRIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84959893930     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)00071-2     Document Type: Article

References (30)

1. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634-653.
2. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010, 50:1091-1100.
3. Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011, 17:1859-1867.
4. Chamilos G, Lewis RE, Kontoyiannis DP Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008, 47:503-509.
5. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014, 20(suppl 3):5-26.
6. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007, 51:2587-2590.
7. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006, 50:2009-2015.
8. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004, 351:1391-1402.
9. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006, 50:126-133.
10. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42:e61-e65.
11. Miceli MH, Kauffman CA Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis 2015, 61:1558-1565.
12. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
13. Choice of Control Group and Related Issues in Clinical Trials US Food and Drug Administration, (accessed March 12, 2015). http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073139.pdf.
14. Rüping MJ, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010, 65:296-302.
15. Chakrabarti A, Shivaprakash MR, Curfs-Breuker I, Baghela A, Klaassen CH, Meis JF Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern. J Clin Microbiol 2010, 48:4580-4585.
16. Lanternier F, Dannaoui E, Morizot G, et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis 2012, 54(suppl 1):S35-S43.
17. Shoham S, Magill SS, Merz WG, et al. Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases. Med Mycol 2010, 48:511-517.
18. Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009, 200:1002-1011.
19. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008, 47:674-683.
20. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, second edition, CLSI document M38-A2 2008 2008, Clinical and Laboratory Standards Institute, Clinical and Laboratory Standards Institute, Wayne, PA.
21. Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016, 387:760-769.
22. Kara IO, Tasova Y, Uguz A, Sahin B Mucormycosis-associated fungal infections in patients with haematologic malignancies. Int J Clin Pract 2009, 63:134-139.
23. Lanternier F, Poiree S, Elie C, et al. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother 2015, 70:3116-3123.
24. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
25. Lewis RE, Albert ND, Kontoyiannis DP Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis. Antimicrob Agents Chemother 2014, 58:6767-6772.
26. Luo G, Gebremariam T, Lee H, Edwards JE, Kovanda L, Ibrahim AS Isavuconazole therapy protects immunosuppressed mice from mucormycosis. Antimicrob Agents Chemother 2014, 58:2450-2453.
27. Luo G, Gebremariam T, Lee H, et al. Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis. Antimicrob Agents Chemother 2013, 57:3340-3347.
28. Bacher P, Steinbach A, Kniemeyer O, et al. Fungus-specific CD4(+) T cells for rapid identification of invasive pulmonary mold infection. Am J Respir Crit Care Med 2015, 191:348-352.
29. Koo S, Thomas HR, Daniels SD, et al. A breath fungal secondary metabolite signature to diagnose invasive aspergillosis. Clin Infect Dis 2014, 59:1733-1740.
30. Millon L, Larosa F, Lepiller Q, et al. Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients. Clin Infect Dis 2013, 56:e95-101.